Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Hospital Medicine
How would you approach EGPA with renal involvement that was on maintenance Rituximab, last infusion two months ago and develops new onset liver involvement?
Other causes if liver disease excluded.
Related Questions
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
How would you approach the evaluation and management of isolated vasculitis with aneurysms involving the segmental hepatic arteries causing hepatic hemorrhage in an otherwise healthy patient in his 80s?
Would you start anticoagulation in a previously heathy patient with a new diagnosis of ANCA vasculitis (+PR3, RPGN, crescents on kidney biopsy) who presented with pancreatitis, splenic and renal infarcts and was also found to have CMV viremia?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
How would you approach management of a patient with a medium-to-large vessel vasculitis who developed perforation of the stomach and colon on steroids and cyclophosphamide?
Do you send anti-human neutrophil elastase antibodies when you suspect levamisole-induced ANCA vasculitis?
When starting stress dose steroids for patient with primary adrenal insufficiency, how do you decide whether to start hydrocortisone 100 mg every 8 hours versus 50 mg every 6 hours?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
Would you give IVIG for Rituximab induced immunodeficiency in patients with reduced kidney function from renal GPA?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?